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ABSTRACT
A number of important drugs used to treat cancer—many
of which serve as the backbone of modern chemotherapy
regimens—have outdated prescribing information in their
drug labeling. The Food and Drug Administration is under-
taking a pilot project to develop a process and criteria for
updating prescribing information for longstanding oncology
drugs, based on the breadth of knowledge the cancer
community has accumulated with the use of these drugs over
time. This article highlights a number of considerations for
labeling updates, including selecting priorities for updating;
data sources and evidentiary criteria; as well as the risks, chal-
lenges, and opportunities for iterative review to ensure pre-
scribing information for oncology drugs remains relevant to
current clinical practice. The Oncologist 2019;24:1–7
INTRODUCTION
A number of important drugs used to treat cancer—many of
which serve as the backbone of modern chemotherapy
regimens—have outdated information in their drug labeling [1].
This prescribing information is intended to be an authoritative
resource to ensure clinicians are equipped with the information
necessary to safely and effectively prescribe drugs to their
patients. Outdated drug labeling poses a public health chal-
lenge: it undermines the U.S. Food and Drug Administration
(FDA) mission to protect public health by ensuring drug safety
and efﬁcacy. Thus, the FDA is undertaking a pilot project named
Project Renewal to develop a process and criteria for updating
prescribing information for longstanding oncology drugs. The
process and criteria will leverage the breadth of knowledge the
cancer community has accumulated with the use of these drugs
over time, often spanning decades of experience.
The FDA requested that the National Academies of Sci-
ences, Engineering, and Medicine convene experts to discuss
the challenges and opportunities to update labeling for oncol-
ogy drugs that are inconsistent with the current evidence
base and use in clinical practice. The National Academies’
National Cancer Policy Forum, in collaboration with the
Forum on Drug Discovery, Development, and Translation, held
a meeting on this topic in March of 2019 [2]. This article high-
lights a number of considerations for labeling updates, such
as selecting priorities; data sources and evidentiary criteria,
including labeling updates for special populations; and the
risks, challenges, and opportunities for iterative review, to
ensure prescribing information for oncology drugs remains
relevant to current clinical practice.
CHALLENGES OF OUTDATED ONCOLOGY DRUG LABELING
Oncology drug labeling serves several purposes. First, drug
labeling is the legal agreement between the federal govern-
ment and the sponsor of a new drug application (NDA) or a
biologics license application (BLA) regarding the drug’s pre-
scribing information and represents a license to market the
drug for approved uses. Second, drug labeling is intended
to provide clinicians with the information necessary for the
safe and effective use of a drug [3]. Friends of Cancer
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Commentary
Research noted that drug labeling, when kept up-to-date, is
“the most authoritative drug-related information that is
available to prescribers” [4].
However, the prescribing information for a number of
longstanding oncology drugs has become outdated and many
remain in an older format, making it difﬁcult for prescribers
and pharmacists to ﬁnd important information. The format of
drug labeling was revised according to the 2006 Physician
Labeling Rule, but drugs that were approved prior to June 2001
were not required to have their drug labeling modernized [5].
A major reason for outdated labeling is the speed and
volume at which new information that emerges about
drugs in the postmarket setting. Following a drug’s
approval, research and experience with the drug may indi-
cate revised dosing and administration schedules, or they
may provide important information about pharmacology,
side effects, safety concerns, and drug performance in spe-
cial populations (e.g., patients with pediatric cancers or
patients with comorbidities or organ dysfunction). Drug
indications can also become outdated. Prescribing informa-
tion for some drugs may contain indications that are no lon-
ger supported by the evidence base, and others may not
include new indications that would be considered standard
of care by the oncology community.
Outdated labeling is particularly problematic in the con-
text of oncology care, because many chemotherapy treat-
ment protocols involve combination therapies. New agents
are often used in combination with well-established drugs,
but the labeling of older drugs is generally not updated to
reﬂect those uses. There is also a dearth of information in
drug labeling about use in special populations.
Most changes to drug labeling occur at the discretion of
a drug manufacturer. However, certain disincentives—such
as the cost of preparing supplemental applications or generic
competition once a drug goes off patent—may discourage
drug manufacturers from pursuing labeling changes [1]. Dif-
fering regulatory requirements for reference listed drugs
(RLDs; i.e., brand-name drugs) and generic drugs contribute
to outdated and inaccurate labeling over time. Generic drugs
achieve FDA approval through an abbreviated new drug
application (ANDA) and are required to have the same label-
ing as the RLD at the time of the ANDA approval, with certain
exceptions [6–8]. Manufacturers of generic drugs are not
able to independently update product labeling without jeop-
ardizing their generic status, because of the “sameness”
requirement under the Hatch-Waxman Amendments to the
Federal Food, Drug, and Cosmetic Act. The act mandates that
generics have the same active ingredients, strength, dosage,
indications, and safety labeling as the RLD. In 2013, the FDA
issued a proposed rule to permit generic manufacturers to dis-
tribute revised product labeling that differs in certain respects,
on a temporary basis, from the labeling of its RLD upon sub-
mission to the FDA of a “changes being effected” supplement
[9]. However, the FDA has not yet issued a ﬁnal rule.
It is not uncommon for the RLD to be discontinued or
withdrawn for reasons other than safety or effectiveness,
especially for older products [4]. When the RLD has been
withdrawn, labeling updates are not initiated by the RLD
holder. When an RLD has been discontinued, the RLD holder
is required to continue to update the labeling, but is
unlikely to be motivated to submit supplemental NDAs for
additional indications. Furthermore, the generic drug indus-
try may not have the infrastructure or business model to
submit efﬁcacy supplements based on updated evidence.
PROJECT RENEWAL
A white paper from Friends of Cancer Research noted that
outdated prescribing information leads clinicians to rely on
sources other than drug labeling to guide their decision
making for patient treatment. It also reduces the FDA’s abil-
ity to convey accurate and reliable information about drugs
to patients and clinicians [1, 4]. Project Renewal aims to
provide clinicians and their patients with the most accurate
drug labeling by developing a process and criteria for
updating prescribing information for longstanding oncology
drugs, based on the breadth of experience the cancer com-
munity has accumulated with using these drugs. The FDA
has noted that this pilot is not intended to expand indica-
tions for drugs on patent or with exclusivity; to review all
possible indications for a particular drug; or to affect cost,
payment, or coverage decisions.
The FDA is planning to review and update prescribing
information for approximately 30–40 longstanding oncology
drugs. There are 17 drug labeling sections that may need to
be updated for such drugs (Fig. 1). One example of an
oncology drug whose prescribing information was recently
updated is ﬂuorouracil. The prescribing information was
reorganized into the new format, and several sections were
updated, including the following changes [10]: dosing and
administration: indications were reorganized and clariﬁed,
and dosing and administration for each indication were
updated; safety: contraindications were revised and new
warnings were added for several common toxicities associ-
ated with warfarin use, such as cardiac and neurologic tox-
icity; clinical pharmacology: a warning was added regarding
increased risk among individuals who have low or absent
activity of a speciﬁc enzyme; and an outdated black box
warning was removed.
For a new indication to be added to drug labeling, the
FDA is required to assess whether there is substantial evi-
dence of efﬁcacy, deﬁned as:
Evidence consisting of adequate and well-controlled
investigations, including clinical investigations, by experts
qualiﬁed by scientiﬁc training and experience to evaluate
the effectiveness of the drug involved, on the basis of which
it could fairly and responsibly be concluded by such experts
that the drug will have the effect it purports or is represen-
ted to have under the conditions of use prescribed, rec-
ommended, or suggested in the labeling or proposed
labeling thereof [11].
Five elements of substantial evidence include [10]: quan-
tity of evidence (number of clinical trials and supportive evi-
dence); quality of evidence (adequate and well-controlled
clinical trials); magnitude and statistical persuasiveness of
the result (e.g., large, statistically signiﬁcant overall survival
improvement); source of evidence (controlled clinical trials,
real-world evidence, published literature); and context (rarity
© 2019 The Authors.
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of the disease, unmet need, safety and efﬁcacy data across
diseases).
This article describes several factors to consider when
assessing the evidence base for labeling updates, including
which labeling sections are priorities for updates; what
sources of information and study designs could be
reviewed; the quality, quantity, and types of evidence that
would be considered adequate to update different sections
of drug labeling; and challenges and risks to developing a
process and criteria for updating drug labeling.
SELECTING PRIORITIES FOR LABELING UPDATES
Numerous sections of drug labeling could be prioritized for
updating. One of the factors that could be considered is
whether current information is accessible in an alternate
source separate from drug labeling. For example, guidance
about off-label uses of oncology drugs is widely available in
various drug compendia. Therefore, updating the indication
section may be of lower priority than other labeling sec-
tions. Instead, updating important information about safety
or use in special populations or ensuring that dosage and
administration information is current may be higher priori-
ties. In particular, specifying dose modiﬁcation strategies
that mitigate toxicity while preserving efﬁcacy, or how dos-
age should be modiﬁed based on a patient’s comorbidities,
may be useful updates to drug labeling. New risks, particu-
larly those severe enough to warrant a warning, or observed
drug-drug interactions would also constitute critical informa-
tion to update. Another priority is information about use in
pediatric, pregnant, or older adult cancer populations, espe-
cially given the limited drug development activity focused
on these populations. Other areas of emphasis include
updated pharmaceutical and admixture data and additional
pharmacology information. For example, food effect and
organ impairment studies may provide important informa-
tion for prescribers.
SOURCES OF INFORMATION AND STUDY DESIGNS
One of the challenges to updating drug labeling is that
much of the data that can be used to update prescribing
information for longstanding drugs have not been gener-
ated with this purpose in mind. Drug sponsors typically col-
lect data with the intent to submit it to the FDA to review
Drug Labeling Sections
1. Indications and Usage 
2. Dosage and Administration 
3. Dosage Forms and Strengths 
4. Contraindications 
5. Warnings and Precautions 
6. Adverse Reactions 
7. Drug Interactions 
8. Use in Specific Populations 
9. Drug Abuse and Dependence 
10. Overdosage 
11. Description 
12. Clinical Pharmacology 
13. Nonclinical Toxicology 
14. Clinical Studies 
15. References 
16. How Supplied/Storage and Handling 
17. Patient Counseling Information
Figure 1. Full prescribing information: Contents, from the FDA
Guidance for industry: Labeling for human prescription drug
and biological products [26].
Table 1. Examples of factors to consider to determine
whether data is ﬁt-for-purpose for a labeling update
Factors Questions to Consider
Volume of data How many data are available to consider a
proposed labeling update?
Do the data come from one source or
multiple sources?
Is the volume of data sufﬁcient to draw an
appropriate conclusion, acknowledging
that this decision may vary depending on
the population under consideration (e.g.,
a lower volume of data may be
appropriate for rare cancers or special
populations, such as pediatric patients
with cancer)?
Volume of
experience
What is the clinical familiarity with the
drug?
How many years has the drug been in use?
Is the proposed labeling update considered
standard of care in oncology practice?
Is the experience with the drug reﬂective of
modern oncology practice, or is the
experience reﬂective of historical
practice?
Longitudinal
follow-up
Are data available to assess patient
outcomes over extended periods of time?
Is longitudinal follow-up reﬂective of
current oncology practice?
Disparate
studies
Are there conﬂicting studies that call into
question a proposed labeling update?
How do the quality and quantity of
conﬂicting studies compare to those that
support a labeling update?
Quality of the
data
What is the rigor of the study design?
Is the proportion of missing data
reasonable?
What is the follow-up period?
What are the number of events for the
primary endpoint?
Can data quality be systematically assessed?
Relevance of
the data
Are the data available directly related to the
proposed labeling update, or are the data
being extrapolated from a differing
population or geographic region, or
clinical question?
Are the data able to be directly derived
from the drug, as opposed to a drug
combination?
Risk of being
incorrect
If the labeling update is later determined to
be wrong, what are the clinical
consequences?
© 2019 The Authors.
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as an NDA, BLA, or supplemental application. However, the
data that are available to update longstanding oncology
drugs may have been collected by academic investigators,
cooperative clinical trial groups, cancer centers, or other
stakeholders and may vary in the quality and scientiﬁc rigor
used to collect them, in quantity, and in completeness.
Although these distinctions are important to acknowledge,
it is also important to recognize that the oncology commu-
nity has had years—and sometimes decades—of experience
with these drugs, which may help to address some of the
scientiﬁc gaps in knowledge.
Project Renewal has focused on identifying and codify-
ing existing data and considering how to best evaluate and
use this information to update drug labeling. Multiple
sources of data exist, and some may be more useful than
others for this project. Thus, it will be important to consider
all potential data sources that could inform a decision to
update labeling. The FDA may place greater reliance on cer-
tain sources, but it is important to identify and consider all
sources of data, unless it can be concluded that speciﬁc
data are irrelevant or inaccurate. The following potential
data sources and study designs could be considered: meta-
analyses of randomized phase II and phase III clinical trials
(study-level data); randomized controlled clinical trials; pro-
spective, noncomparative clinical trials (e.g., phase II stud-
ies); real-world data (electronic health records, registry
data, administrative claims data, adverse events reporting
databases); case series based on historical control groups;
“case-control” observational studies; modeling and com-
puter simulation data; case series with literature controls;
case series without controls; and case reports.
In addition to reviewing the types of data sources that
may be used to update drug labeling, there are other fac-
tors that need to be considered to determine whether data
is ﬁt-for-purpose for a proposed labeling update (Table 1).
These considerations can also be useful when compiling
information from multiple data sources or multiple studies
and are conceptually similar to the checklist for ensuring
real-world data are appropriate for regulatory applica-
tions [12].
As a general approach, it would be beneﬁcial to review
the totality of the evidence when updating prescribing
information for longstanding drugs, rather than specifying
which data sources may be in scope versus out of scope.
EVIDENTIARY PROCESSES AND CRITERIA
Prospectively specifying criteria that are necessary to update
labeling for longstanding oncology drugs and making these
criteria transparent to the cancer community would help
advance the goal of keeping labels accurate. Because of the
rigor required for labeling updates and the consequent impact
on prescribing practices, it is understandable that drug label-
ing will continue to have a conservative bias. The updated
prescribing information will not necessarily be inclusive of
all possible indications, nor will it reﬂect all available informa-
tion on dosing, administration, safety, pharmacology, or other
information contained in drug labeling sections.
Numerous evidence assessment methodologies and pro-
cesses that can inform the these labeling updates, including
those used in the development of clinical practice guidelines,
drug compendia, and reporting guidelines, such as those com-
piled by the EQUATOR Network [13]. Compendia and clinical
practice guidelines represent a synthesis of available informa-
tion to inform decision making in oncology practice. These
resources are compiled in numerous ways according to vari-
ous criteria, and they often involve incorporation of expert
opinion. Because of varying degrees of scientiﬁc rigor used
within these resources, they may serve as a necessary, but
not sufﬁcient, step to identifying potential updates to pre-
scribing information for longstanding oncology drugs. It is also
important to recognize that the purpose of clinical practice
guidelines and compendia is to inform important clinical
questions (e.g., selection of optimal adjuvant chemotherapy
and targeted therapy for patients with early stage breast can-
cer), and not to evaluate one speciﬁc oncology drug [14].
Another key component of a high-quality evidence
review process is ensuring appropriate content and process
expertise. This requires the engagement of trained system-
atic reviewers with oncology care knowledge, statisticians,
and content experts.
It is likely that updates of certain labeling sections will
require more data of higher quality than others. New indica-
tions, which need to meet the substantial evidence require-
ment, will require a high degree of supporting information.
The threshold to update safety information in drug labeling
may be lower than that for updating a new indication. How-
ever, one caveat may be that if a safety signal comes with a
recommended course of action (e.g., if a speciﬁc adverse
event is observed, the dose should be modiﬁed), the evi-
dence to support the recommendation needs to be strong to
ensure conﬁdence that the strategy is effective in mitigating
toxicity while preserving acceptable efﬁcacy. This also
ensures that unreliable information about potential harms
does not undermine the effectiveness of the treatment.
Figure 2 illustrates the authors’ thinking on which spe-
ciﬁc sources of information are likely to best inform labeling
updates for different types of information, such as indica-
tions, dosing, administration, safety, and use in special
populations. The data sources are organized conceptually in
order of their comparative scientiﬁc strength (although the
authors recognize that the hierarchy may not be
static—e.g., a large, appropriately powered, and well-
designed clinical trial may be stronger evidence than a less-
rigorous meta-analysis). Because many of these decisions
will be subjective and context dependent, Figure 2 classiﬁes
the utility as high, medium, and low.
SPECIAL POPULATIONS
There is a paucity of information about the use of oncology
drugs in special populations, including pediatric patients with
cancer, older adults, individuals with comorbidities or organ
dysfunction, and pregnant women [15–17]. Eligibility criteria
in oncology clinical trials often limit participation of special
populations in clinical research, particularly very young chil-
dren or those with very rare diseases [17, 18]. However,
more recent pediatric oncology clinical trials, particularly for
newly diagnosed patients, tend to have broader eligibility
criteria. The rarity of certain cancers also contributes to
© 2019 The Authors.
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limited information about how drugs perform in these con-
texts. To help address this challenge, FDA has developed sev-
eral draft guidances to encourage researchers and drug
developers to broaden eligibility criteria and to provide
strong scientiﬁc rationale for limiting participation on clinical
trials [19–21].
A majority of children with cancer are treated in aca-
demic medical centers using drug combination strategies that
stem from clinical trial protocols. However, most children are
treated off label, owing to the limited number of oncology
drugs approved for pediatric indications [22]. There are a
number of scientiﬁc challenges that contribute to limited
pediatric cancer drug development, including a lack of under-
standing drug metabolism in a variety of age cohorts; limited
availability of pediatric-friendly formulations of the drug; a
lack of understanding of the acute and long-term toxicities in
the context of normal development; determination of ade-
quate central nervous system penetration in speciﬁc disease
contexts (e.g., central nervous system tumors, meningeal leu-
kemia); and scarcity of population pharmacokinetic data
among children with cancer.
Data to inform pediatric prescribing are an important
drug labeling need. The rareness of pediatric cancers limits
the availability of randomized controlled clinical trial data
that could inform drug labeling.
Oftentimes, research evaluating how oncology drugs
perform in older patients and those who have comorbidities
or organ dysfunction (which are common conditions among
older adults) is conducted following FDA approval and there-
fore not included in initial drug labeling. However, this
information is critical to include in labeling because patients
who participate in clinical trials are often not representative
of the broader population of patients treated in community
oncology practice. Clinical trial participants tend to be youn-
ger and healthier, but older adults—including those who
have comorbidities or organ dysfunction—often respond dif-
ferently to treatments than do younger patients. Older
patients are also more sensitive to drug toxicities and side
effects [16]. In addition, chronological age can be an inade-
quate method for characterizing individuals, and clinicians
often perform geriatric assessments to determine whether a
patient is ﬁt, vulnerable, or frail. If the assessment suggests
a patient is frail, clinicians may modify the dose, schedule,
or components of a cancer regimen so that the regimen is
better tolerated. For example, a frail, older adult patient
may be prescribed a two-drug combination rather than a
three-drug combination. To better inform prescribing deci-
sions for these populations, pharmacokinetic and adverse
event data, as well as effective dose and schedule modiﬁca-
tion strategies, are particularly important to review for label-
ing updates.
For patients with rare cancers and those who have com-
orbidities and organ dysfunction, real-world data may be a
particularly important resource to consider when updating
drug labeling. Leveraging real-world data for labeling
updates is consistent with ongoing initiatives to use real-
world evidence to inform regulatory decision making,
including a draft FDA guidance on the topic [23] and ongo-
ing research assessing the potential validity of endpoints
derived from real-world data [24].
Figure 2. Potential utility of an information source to inform different types of labeling updates
*High utility = dark blue; medium utility = blue; low utility = light blue. This table represents a general schematic. Although utility
has been visualized as three distinct categories, there can be substantial variability within each category. Further work could reﬁne
the utility of different information sources by using a Likert scale. In addition, the quality of the sources of information can vary
widely, which could affect assessment of the strength of evidence.
**Randomized controlled clinical trials include phase III and some phase II studies.
Hierarchy of Strength of Evidence draws on the conceptual framing from Green SB, Byar DP. Using observational data from regis-
tries to compare data: The fallacy of omnimetrics. Stat Med 1984;3:361–373 [27].
© 2019 The Authors.
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CHALLENGES AND RISKS RELATED TO UPDATING PRESCRIBING
INFORMATION
A primary objective of developing a process and criteria to
update drug labeling is to overcome a common challenge in
drug development: after FDA approval, a substantial
amount of evidence about oncology drugs is accrued in the
postmarket setting, but oftentimes this knowledge is not
reﬂected in drug labeling. Over time, this has resulted in
important, well-established oncology drugs with outdated
prescribing information.
Correcting outdated prescribing information presents
many risks and challenges. One concern is whether this pro-
cess will add important new prescribing information or
whether the updates will primarily be directed at organiza-
tion and formatting to meet the requirements of the 2006
Physician Labeling Rule. There is an inherent tension in
updating labeling: a reluctance to update prescribing infor-
mation without a sufﬁcient level of evidence versus the
need to use data that were never collected with this pur-
pose in mind. This tension may result in relatively few
updates. Differing evidence requirements for distinct label-
ing sections also adds complexity to this process.
The availability of information to update safety in drug
labeling may be an additional challenge. Much of the safety
information stems from uncontrolled data sources, such as
registries. However, low rates of reporting through
MedWatch and other safety registries may restrict the
information available to guide labeling updates. Attribution
of safety events to a particular oncology drug in a combina-
tion regimen may be difﬁcult. For longstanding oncology
drugs, some safety data may also be irrelevant to modern
oncology practice, because of advances in supportive care
and strategies to prevent and manage side effects.
Another challenge is the pace of oncology research.
Even if the prescribing information for a speciﬁc drug is
updated, new research—such as results of pivotal clinical
trials presented at scientiﬁc conferences—can necessitate
additional labeling changes. The speed at which data are
acquired in the postmarket setting makes keeping prescrib-
ing information up to date difﬁcult. The need for labeling
changes, coupled with the time it takes to update labeling,
is likely to require signiﬁcant resources. Thus, it is important
to determine whether efforts to update labeling are sus-
tainable and scalable. Is it possible to continue updates to
longstanding oncology drugs, given the enormous workload
and resources needed to identify outdated prescribing
information, review the literature to determine whether
and how labeling should be updated, and then prepare and
vet the updates? Is this process scalable to update prescrib-
ing information for drugs in all therapeutic areas?
FUTURE DIRECTIONS AND OPPORTUNITIES: TOWARD
ITERATIVE REVIEW AND UPDATING
The FDA is intended to be an impartial, authoritative source
of information about oncology drugs. The FDA’s process of
reviewing data is trusted, rigorous, transparent, and con-
ducted by expert reviewers with no ﬁnancial ties to industry
[14, 25]. Data provided in drug labeling are also freely and
publicly available to practicing clinicians, whereas informa-
tion in the published literature may be inaccessible, because
of article ﬁrewalls and journal subscription fees [25]. Thus,
establishing a process to iteratively review and update drug
labeling serves an important public health objective.
Richard Pazdur, director of the FDA Oncology Center of
Excellence, has noted that the drug label “is a living docu-
ment. Many people have the misconception that the history
of the drug ends with the approval of the drug. Really, that
is just the beginning….We have to keep that in mind and
also have a process of updating these labels.”
Given the speed and volume of new advances in cancer
research and drug development, it is unlikely that drug label-
ing could keep pace. However, FDA could engage with leaders
in the oncology community to prioritize drugs that are in need
of updated labeling. In addition, important new research stud-
ies involving longstanding oncology drugs could serve as trig-
gers to update labeling for speciﬁc drugs. Soliciting requests
from the public—including oncologists, pharmacists, nurses,
patients, and other stakeholders—could also serve as a mech-
anism to update speciﬁc information in drug labeling.
Another potential opportunity is to explicitly list when
the prescribing information for a speciﬁc drug was last
updated. This information could provide important insights
to oncology clinicians, especially given the challenge of
keeping prescribing information updated.
Novel data sources and analytic methodologies could
serve as critical inputs to updating oncology drug labels in
the future. Leveraging data collected in real-world settings
could provide important information on the effectiveness
and safety of drugs as used in clinical practice, including use
in patients with rare cancers, comorbidities, and organ
dysfunction.
GLOSSARY OF TERMS
Compendia: Privately owned pharmaceutical reference guides that are used
to inform coverage decisions for oncology drugs that are used in an off
label context.a
Discontinued drug: As deﬁned by the FDA, a drug product that has never
been marketed, has been discontinued from marketing, is for military
use, is for export only, or has had its approval withdrawn for reasons
other than safety or efﬁcacy after being discontinued from marketing.b
Informally, discontinued drugs are often products that are not marketed,
but the relevant new drug application (NDA) is still “approved” by the
FDA, such that the applicant could recommence marketing at any time.
Drug labeling: The prescribing information for a prescription drug.
Indication: The disease context in which a drug has approved for use by the
FDA (e.g., cancer site, stage, and line of therapy). Oncology clinicians may
prescribe drugs “on label” (according to the indications speciﬁed in the
prescribing information) or “off label” (i.e., for diseases that are not spec-
iﬁed in the prescribing information). Many off-label uses of oncology
drugs are considered standard of care and are supported by clinical trials,
drug compendia, or clinical practice guidelines. However, some off-label
uses are supported by stronger evidence than others.c
Withdrawn: A drug whose NDA is no longer considered approved by the
FDA such that the product cannot be lawfully marketed.d
Notes:
aGreen, AK, Wood WA, Basch EM. Time to reassess the cancer compendia for off-label
drug coverage in oncology. JAMA 2016;316:1541–1542.
bFood and Drug Administration. 2019. Approved drugs with therapeutic equivalence
evaluations, 39th ed. Washington, DC. Available at https://www.fda.gov/media/71474/
download. Accessed August 14, 2019.
cConti, RM, Bernstein AC,Villaﬂor VM et al. Prevalence of off-label use and spending in
2010 among patent-protected chemotherapies in a population-based cohort of medical
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